Organogenesis Holdings Inc.
Organogenesis Holdings Inc. (ORGO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
orgo · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Organogenesis Holdings Inc. (ORGO) measures how much investors pay for each dollar of the company's trailing earnings. ORGO's current PE ratio of N/A is calculated by dividing its stock price of $2.38 by its TTM earnings per share of -$0.00.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2015 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 6 fiscal years · Front-end computedMinQ1 · 25%34.8x
MedianQ3 · 75%489.4x
Max
At N/A, ORGO's current P/E is lower than in 0% of its annual fiscal year readings over the past 6 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Organogenesis Holdings Inc.You ORGO | $306M | N/A | — | -$0.00 |
 AngioDynamics, Inc. ANGO | $493M | N/A | — | -$0.83 |
 Bicycle Therapeutics plc BCYC | $285M | N/A | — | -$3.16 |
 Compass Therapeutics, Inc. CMPX | $279M | N/A | — | -$0.42 |
 Emergent BioSolutions Inc. EBS | $413M | 12.57x | — | $0.98 |
 Evolus, Inc. EOLS | $440M | N/A | — | -$0.80 |
 Esperion Therapeutics, Inc. ESPR | $655M | N/A | — | -$0.11 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 17.73x | $0.29 | -96.4% | |
2024-12-31 FY2024 | 489.38x | $0.01 | +350.9% | |
2023-12-31 FY2023 | 108.54x | $0.04 | +381.8% | |
2022-12-31 FY2022 | 22.53x | $0.12 | +79.0% | |
2021-12-31 FY2021 | 12.59x | $0.73 | -73.3% | |
2020-12-31 FY2020 | 47.07x | $0.16 | — | |
2019-12-31 FY2019 | — | $-0.42 | — | |
2018-12-31 FY2018 | — | $-0.94 | — | |
2017-12-31 FY2017 | — | $-0.03 | — | |
2016-12-31 FY2016 | — | $-0.02 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Organogenesis Holdings Inc. (ORGO) measures how much investors pay for each dollar of the company's trailing earnings. ORGO's current PE ratio of N/A is calculated by dividing its stock price of $2.38 by its TTM earnings per share of -$0.00.
Frequently asked questions
ORGO pe ratio · 6 questionsORGO's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.38 and TTM EPS of -$0.00. Data sourced from Financial Modeling Prep via ORGO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Organogenesis Holdings Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09